Latest Regulatory News

Western Gold Resources Limited has had its trading suspension lifted following the release of initial assay results from its Duke Gold project and a response to an ASX price and volume query.

Tempest Minerals has secured regulatory approval to begin Phase I drilling at its Halo prospect within the Yalgoo Project, targeting iron, copper, and gold. A heritage survey with the Badimia People is currently in progress, marking a key step toward unlocking the site's potential.

Highfield Resources has requested a voluntary suspension of its shares on the ASX to complete a capital raising, with trading expected to resume by 23 September 2025.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

Prospech Limited’s PRSO securities have been suspended from trading pending compliance with ASX rules, raising questions about the company’s regulatory standing.

Mont Royal Resources Ltd (ASX – MRZ) has lodged a prospectus to raise between A$8 million and A$10 million through a share offer priced at A$0.20 each, coinciding with a proposed merger with Commerce Resources Corp (TSXV – CCE). The combined entity aims to become a leading Quebec-focused critical minerals developer.

Argent Minerals has reported outstanding high-grade silver and polymetallic mineralisation from diamond drillhole AKDD208 at its Kempfield Project, significantly enhancing the deposit’s resource potential.

Forrestania Resources has completed its acquisition of the British Hill Gold Project near Southern Cross, Western Australia, and appointed MBS Environmental to lead mine development planning.

OncoSil Medical’s PANCOSIL Phase 1-2 study reveals promising safety and feasibility for a novel CT-guided pancreatic cancer therapy, with survival outcomes exceeding historical benchmarks.

Imricor Medical Systems has successfully completed a comprehensive Human Factors study for all its devices under FDA review, marking a critical milestone towards U.S. market entry. The extensive 7-month study involved 46 healthcare professionals and tested nine products, underscoring Imricor’s growing momentum in electrophysiology innovation.

360 Capital Mortgage REIT (ASX, TCF) has initiated a non-renounceable 1-for-1 entitlement offer priced at $5.94 per unit, aiming to raise approximately $45.2 million to fund new loan investments and expand its portfolio.